Comparison of Two Trap Net Designs for Sampling Muskellunge

Sampling adequate numbers of muskellunge (Esox masquinongy) is necessary to evaluate stocking success and to collect information on various population metrics (e.g., growth, condition, relative abundance). However, muskellunge are often difficult to sample with standard fish sampling gears. We collected muskellunge in trap nets of two different designs (large trap nets [1.5-m × 1.8-m frames, 1.5-m diameter hoops, double throated, single 1.5-m × 30.5-m lead and 19-mm knotless mesh] and small trap nets [0.9-m × 1.5-m frames, 0.9-m diameter hoops, single throat, single 0.9-m × 15.2-m lead and 19-mm knotted mesh]. We also estimated abundance of muskellunge (\u3e600 mm total length) in three eastern South Dakota waters using marked and recaptured fish collected from the trap net comparisons. Sampling with both large and small trap nets was completed during thespring of 2013 and 2014 soon after ice-out. More muskellunge were collected in large than small trap nets at all three lakes. Mean total lengths of muskellunge did not differ significantly between large and small trap nets; however, length-frequency distribu- tions did differ between net designs. Regardless of trap net design, a small number of muskellunge were collected, likely due to low abundance (population range = 0.10 fish/ha to 0.47 fish/ha) in these populations. Thus, long-term monitoring is necessary to accurately assess populations and associated trends. Sampling with large trap nets during the spring combined with population estimates may improve the ability to monitor and manage muskellunge when compared to sampling with small trap nets

FUSE Observations of Molecular Hydrogen in Translucent Interstellar Clouds: The Line of Sight Toward HD 73882

We report the results of initial FUSE observations of molecular hydrogen (H2) in translucent clouds. These clouds have greater optical depth than any of the diffuse clouds previously observed for far-UV H2 absorption, and provide new insights into the physics and chemistry of such regions. Our initial results involve observations of HD 73882, a well-studied southern hemisphere star lying behind substantial interstellar material (E(B-V) = 0.72; A_V = 2.44). We find a total H2 column density, N(H2) = 1.2 x 10^{21} cm^{-2}, about three times larger than the values for diffuse clouds previously measured in the far-UV. The gas kinetic temperature indicated by the ratio N(J=1)/N(J=0) is 58 +/- 10 K. With the aid of ground-based data to calculate an appropriate multi-component curve of growth, we have determined column densities for all rotational levels up to J = 7. The J >= 2 states can be reasonably fitted with a rotational excitation temperature of 307 +/- 23 K. Both the kinetic and rotational temperatures are similar to those found in previous investigations of diffuse clouds. The ratios of carbonaceous molecules to hydrogen molecules are also similar to ratios in diffuse clouds, suggesting a similar chemistry for this line of sight.Comment: 7 pages, 3 figures, to appear in ApJ Letters (FUSE first-results issue

Intermediate scale structure of the interstellar medium towards NGC 6231 in Sco OB1 with FUSE

The FUSE far-ultraviolet interstellar spectra toward seven targets in NGC 6231 show that the molecules H_2, HD, and CO as well as various atomic species are distributed in several clouds. The main absorption component found on the sight lines lies in the Lupus cloud region at a distance of about 150 pc, and there is a weaker second one, presumably in the Sco OB1 shell surrounding NGC 6231 (d~1.8 kpc). H_2 excitation modelling is used to constrain the radiation field and the density in the gas; HD is used to estimate the abundance of H+. The small angular separation of the target stars allows column density variations to be probed over the field of view, on scales of 0.05 pc in the case of the Lupus cloud distance. They are 40% for H_2 and 60% for H I. A rather strong radiation field inside the molecular clouds suggests a separation of the gas into smaller cloudlets also along the line of sight.Comment: 12 pages, accepted for publication in Astronomy & Astrophysic

Magnetocrystalline Anisotropy Energy of Transition Metal Thin Films: A Non-perturbative Theory

The magnetocrystalline anisotropy energy E(anis) of free-standing monolayers and thin films of Fe and Ni is determined using two different semi-empirical schemes. Within a tight-binding calculation for the 3d bands alone, we analyze in detail the relation between bandstructure and E(anis), treating spin-orbit coupling non-pertubatively. We find important contributions to E(anis) due to the lifting of band degeneracies near the Fermi level by SOC. The important role of degeneracies is supported by the calculation of the electron temperature dependence of the magnetocrystalline anisotropy energy, which decreases with the temperature increasing on a scale of several hundred K. In general, E(anis) scales with the square of the SOC constant. Including 4s bands and s-d hybridization, the combined interpolation scheme yields anisotropy energies that quantitatively agree well with experiments for Fe and Ni monolayers on Cu(001). Finally, the anisotropy energy is calculated for systems of up to 14 layers. Even after including s-bands and for multilayers, the importance of degeneracies persists. Considering a fixed fct-Fe structure, we find a reorientation of the magnetization from perpendicular to in-plane at about 4 layers. For Ni, we find the correct in-plane easy-axis for the monolayer. However, since the anisotropy energy remains nearly constant, we do not find the experimentally observed reorientation.Comment: 15 pages, Revtex, 15 postscript figure

First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07)

Background: Oral temozolomide has shown similar efficacy to dacarbazine in phase III trials with median progression-free survival (PFS) of 2.1 months. Bevacizumab has an inhibitory effect on the proliferation of melanoma and sprouting endothelial cells. We evaluated the addition of bevacizumab to temozolomide to improve efficacy in stage IV melanoma. Patients and methods: Previously untreated metastatic melanoma patients with Eastern Cooperative Oncology Group performance status of two or more were treated with temozolomide 150 mg/m2 days 1-7 orally and bevacizumab 10 mg/kg body weight i.v. day 1 every 2 weeks until disease progression or unacceptable toxicity. The primary end point was disease stabilisation rate [complete response (CR), partial response (PR) or stable disease (SD)] at week 12 (DSR12); secondary end points were best overall response, PFS, overall survival (OS) and adverse events. Results: Sixty-two patients (median age 59 years) enrolled at nine Swiss centres. DSR12 was 52% (PR: 10 patients and SD: 22 patients). Confirmed overall response rate was 16.1% (CR: 1 patient and PR: 9 patients). Median PFS and OS were 4.2 and 9.6 months. OS (12.0 versus 9.2 months; P = 0.014) was higher in BRAF V600E wild-type patients. Conclusions: The primary end point was surpassed showing promising activity of this bevacizumab/temozolomide combination with a favourable toxicity profile. Response and OS were significantly higher in BRAF wild-type patient

Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data.

The impact of HER2-targeted therapy alone followed by the addition of chemotherapy at disease progression (PD) versus upfront combination was investigated by the SAKK 22/99 trial. The aim of this exploratory analysis of the SAKK 22/99 trial was to characterize the specific subset of patients deriving long-term benefit from trastuzumab monotherapy alone and to identify potential predictive factors of long-term response. This is an unplanned post-hoc analysis of patients randomized to Arm A (trastuzumab monotherapy). Patients were divided in two groups: patients with durable clinical benefit from trastuzumab monotherapy and short-term responders without durable clinical benefit from trastuzumab monotherapy Univariate and multivariate analyses of clinical characteristics correlating with response duration was performed. Eighty six patients were randomized in arm A, 24 patients (28%) were long-term responders and 62 (72%) were short-term responders with a 5y-overall survival (OS) of 54% (95% CI 31-72) and of 18% (95%CI 10-30), respectively. Absence of ER expression, absence of PgR expression and presence of visceral disease emerged as possible negative predictive factors for durable clinical benefit. Durable clinical benefit can be achieved with trastuzumab monotherapy in a subgroup of HER2-positive patients with advanced disease and it is predictive for longer OS. Further investigations of predictive biomarkers are necessary to better characterize this subgroup of patients and develop further de-escalating strategies. NCT00004935 ; first posted 27.01.2003, retrospectively registered

Schwinger boson theory of anisotropic ferromagnetic ultrathin films

Ferromagnetic thin films with magnetic single-ion anisotropies are studied within the framework of Schwinger bosonization of a quantum Heisenberg model. Two alternative bosonizations are discussed. We show that qualitatively correct results are obtained even at the mean-field level of the theory, similar to Schwinger boson results for other magnetic systems. In particular, the Mermin-Wagner theorem is satisfied: a spontaneous magnetization at finite temperatures is not found if the ground state of the anisotropic system exhibits a continuous degeneracy. We calculate the magnetization and effective anisotropies as functions of exchange interaction, magnetic anisotropies, external magnetic field, and temperature for arbitrary values of the spin quantum number. Magnetic reorientation transitions and effective anisotropies are discussed. The results obtained by Schwinger boson mean-field theory are compared with the many-body Green's function technique.Comment: 14 pages, including 7 EPS figures, minor changes, final version as publishe

Overview of the Far Ultraviolet Spectroscopic Explorer Mission

The Far Ultraviolet Spectroscopic Explorer satellite observes light in the far-ultraviolet spectral region, 905 - 1187 A with high spectral resolution. The instrument consists of four coaligned prime-focus telescopes and Rowland spectrographs with microchannel plate detectors. Two of the telescope channels use Al:LiF coatings for optimum reflectivity from approximately 1000 to 1187 A and the other two use SiC coatings for optimized throughput between 905 and 1105 A. The gratings are holographically ruled to largely correct for astigmatism and to minimize scattered light. The microchannel plate detectors have KBr photocathodes and use photon counting to achieve good quantum efficiency with low background signal. The sensitivity is sufficient to examine reddened lines of sight within the Milky Way as well as active galactic nuclei and QSOs for absorption line studies of both Milky Way and extra-galactic gas clouds. This spectral region contains a number of key scientific diagnostics, including O VI, H I, D I and the strong electronic transitions of H2 and HD.Comment: To appear in FUSE special issue of the Astrophysical Journal Letters. 6 pages + 4 figure